Clinigen 2017 final results
Adjusted gross profit up 22% - driven by organic growth, full year's contribution from Link Healthcare ('Link') and currency benefits
Adjusted EPS up 25% to 41.8p (2016: 33.4p)
Strong cash flow performance with cash generated from operations of £54.7m (2016: £49.4m)
Net debt substantially decreased by £33.1m to £35.0m (2016: £68.1m)
Full year dividend increased 25% to 5.0p (2016: 4.0p)
Strong growth across all operations
Outstanding performance in Africa and Asia Pacific
Dexrazoxane portfolio revitalisation significantly enhanced by EC approval to update product information for Cardioxane, and launch of Totect in US
New simplified reporting structure comprising Clinical Trial Services ('CTS'), Unlicensed Medicines and Commercial Medicines
